• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Equillium Inc (NQ: EQ )

    0.8648 +0.0243 (+2.89%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,653
    Open 0.8511
    Bid (Size) 0.8305 (13)
    Ask (Size) 0.9214 (6)
    Prev. Close 0.8405
    Today's Range 0.8500 - 0.8900
    52wk Range 0.4500 - 3.250
    Shares Outstanding 34,414,149
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
    From Equillium, Inc.
    Via Business Wire
    Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Equillium, Inc.
    Via Business Wire

    Performance

    YTD
    +17.77%
    +17.77%
    1 Month
    -11.29%
    -11.29%
    3 Month
    +27.20%
    +27.20%
    6 Month
    -59.49%
    -59.49%
    1 Year
    +21.26%
    +21.26%

    More News

    Read More
    Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
    From Equillium, Inc.
    Via Business Wire
    EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
    From Equillium Inc.
    Via Business Wire
    Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
    From Equillium, Inc.
    Via Business Wire
    Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
    From Equillium, Inc.
    Via Business Wire
    Equillium to Participate in Upcoming Investor Conferences
    From Equillium, Inc.
    Via Business Wire
    Equillium to be included in the Russell Microcap® Index
    From Equillium, Inc.
    Via Business Wire
    Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Equillium, Inc.
    Via Business Wire
    Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Gold Down 1%; Bath & Body Works Shares Tumble After Q1 Results
    Via Benzinga
    US Stocks Lower; Donaldson Earnings Beat Views
    Via Benzinga
    Topics Earnings
    Exposures Financial
    Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
    From Equillium Inc.
    Via Business Wire
    Equillium to Present at the Jefferies Global Healthcare Conference
    From Equillium, Inc.
    Via Business Wire
    Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
    From Equillium, Inc.
    Via Business Wire
    EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
    From Equillium Inc.
    Via Business Wire
    Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
    From Equillium, Inc.
    Via Business Wire
    Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Equillium, Inc.
    Via Business Wire
    Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
    From Equillium, Inc.
    Via Business Wire
    Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.